Details:
The proceeds will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.
Lead Product(s): Glycoengineered Therapeutics
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $49.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 05, 2021